DAVENPORT, Iowa, May 19, 2025 (GLOBE NEWSWIRE) -- Lee Enterprises, Inc. (NASDAQ: LEE), a leading provider of trusted local news, today announced the company is hosting a “Draw Off” event series that will pair The Wisconsin State Journal’s editorial cartoonist Phil Hands and The Buffalo News’ Pulitzer Prize-winning cartoonist Adam Zyglis with D.J. Coffman, Director of Comics at VeeFriends, the character universe and entertainment company created by serial entrepreneur Gary Vaynerchuk. The events will stream ...

Core Insights - EB Development has acquired over 90% of Eurobio Scientific's share capital, reaching 90.01% ownership [2][3] Company Overview - Eurobio Scientific is a prominent player in in vitro diagnostics, focusing on transplantation, immunology, and infectious diseases [4] - The company provides diagnostic tests and dedicated reagents for research laboratories, including pharmaceutical and biotechnology firms [4] - Eurobio Scientific operates with approximately 320 employees and has production units in the Paris region, Germany, the Netherlands, and the USA, along with subsidiaries in several European countries [4] Shareholder Information - The main shareholders of Eurobio Scientific include IK Partners, NextStage AM, and its directors Jean-Michel Carle and Denis Fortier [5] - Eurobio Scientific's shares are listed on Euronext Growth Paris and are part of various indices, including Euronext Growth BPI Innovation and Next Biotech [5]

Shenzhen, China, May 19, 2025 (GLOBE NEWSWIRE) -- The Bluetooth tracker market has exploded since Apple shook things up with AirTag in 2021, yet every major brand still forces shoppers to pick a side: iPhone or Android. MiLi’s new MiTag Duo ends that dilemma. It is the first Bluetooth tracker that carries official certification from both Apple and Google in a single piece of hardware. With one tap you add it to Find My on iOS, or factory reset and pair it to Find My Device on Android. Switch phones, keep th ...

Transaction Supports Strategic Focus on Core Operations and Balance Sheet StrengthMURRAY, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Security National Financial Corporation (NASDAQ: SNFCA), announced the successful conclusion of its lending transaction which facilitated the development of the Arrowhead Ranch residential project located in Payson, Utah. As a result of this transaction Security National realized “profit-split” income of nearly $4,000,000, which was in addition to the over $3,200,000 in interest a ...

Reference is made to the Company’s announcement dated 3 December 2024 and to the financial calendar of Kaldalón hf. As previously disclosed, the Board of Directors of Kaldalón hf. has approved the publication of additional interim information to be released between the Company’s half-year and full-year financial reports. These interim disclosures will take the form of unaudited trading statements for the first and third quarters, providing insight into the Company’s financial performance, balance sheet posi ...

ROCKVILLE, Md., May 19, 2025 (GLOBE NEWSWIRE) -- Capital Bancorp (NASDAQ: CBNK) announced today the expansion of its Commercial Banking operations in Delaware with the addition of several highly experienced relationship managers. This strategic move marks a key milestone in the Bank’s Mid-Atlantic growth strategy, positioning Capital Bank to serve more businesses across the state of Delaware and surrounding areas. Located in Southern Delaware, Ritchie Francia is a seasoned commercial banker with deep ties t ...

Voltalia announces the appointment of two new Board members, including one independent Voltalia (Euronext Paris, code ISIN: FR0011995588), an international player in renewable energies, announces the appointment of two new board members. Their nomination has been validated by the shareholders during the Voltalia Annual General Meeting held on May 15, 2025 « Following last Thursday's Annual General Meeting, we are pleased to announce the appointment of Bertrand Cousin as an independent Board member, replacin ...

Geneva, Switzerland, May 19, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced results of its 2025 Annual General Meeting (“AGM”) of Shareholders, held in person in NYC on May 19, 2025. During the meeting, shareholders voted in favor of all resolutions put forward, including the re-election of the current seven board members (five of who ...

Core Insights - The study of acoramidis in the ATTRibute-CM trial indicates that early and sustained increases in serum transthyretin (TTR) levels are associated with improved survival outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][2][5] - Acoramidis, a near-complete TTR stabilizer, has shown significant clinical benefits, including reductions in all-cause mortality (ACM) and cardiovascular-related hospitalizations (CVH) [1][6][12] Group 1: Clinical Findings - A 5-mg/dL increase in serum TTR level within 28 days of treatment initiation correlates with a relative risk reduction of mortality of up to 31.6% through Month 30 [1][5] - The ATTRibute-CM study is the first to demonstrate a direct link between increased serum TTR and survival in ATTR-CM patients [1][2] - Acoramidis treatment resulted in a mean increase of 9.1 mg/dL in serum TTR levels within 28 days, which was sustained throughout the 30-month treatment period [5][6] Group 2: Statistical Outcomes - The study reported a 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 [4] - A 50% reduction in the cumulative frequency of CVH events was observed relative to placebo at Month 30 [4] - The analysis showed that the early increase in serum TTR levels was associated with reduced ACM, independent of baseline risk factors [5][6][12] Group 3: Regulatory Approvals - Acoramidis is approved as Attruby™ by the U.S. FDA and as BEYONTTRA by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency [1][7] Group 4: Company Overview - BridgeBio Pharma, Inc. focuses on developing transformative medicines for genetic diseases and has a pipeline that includes advanced clinical trials [10]

Company Information - Spineway is engaged in the design, manufacture, and marketing of innovative implants and surgical instruments for treating severe spinal disorders [7] - The company has an international network of over 50 independent distributors, with more than 70% of its revenue generated from exports [7] Upcoming Events - A Combined General Meeting is scheduled for June 4, 2025, at 2:00 p.m. at the Group's headquarters in Ecully [3] - The notice of the meeting, including the agenda and resolutions, was published on April 30, 2025 [4] - The next financial report, detailing H1 2025 revenue, is expected on July 30, 2025 [5] Regulatory Information - Spineway is eligible for PEA-SME (Equity Savings Plans for SMEs), which may attract certain investors [6] - All preparatory documents for the General Meeting can be accessed on the company's website under "Investors/Regulated Information" [5]